Sun Pharma gets nod from South African regulator for generic semaglutide injection
The approval by the SAHPRA is to manufacture and market the generic version of semaglutide injection in South Africa for the treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise, says Sun Pharmaceutical Industries
· 7/15/2026, 4:26:12 PM· 2 min read
The approval by the SAHPRA is to manufacture and market the generic version of semaglutide injection in South Africa for the treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise, says Sun Pharmaceutical Industries
Read original story →Related stories
business
SpaceX share price drops below stock market debut
business
Cabinet approves ₹1.27 lakh crore for Semicon Mission 2.0, for mobile manufacturing, new highways
business
Indian Gas Exchange files IPO papers with Sebi; parent IEX to divest stake
business